Abstract
Nonpeptide thrombopoietin receptor (TPOR/MPL) agonists, such as eltrombopag, have been used to treat thrombocytopenia of various aetiologies. Here, we investigated the pharmacological properties of hetrombopag, a new orally active small-molecule TPOR agonist, in preclinical models. Hetrombopag specifically stimulated proliferation and/or differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells, with low nanomolar EC50 values through stimulation of STAT, PI3K and ERK signalling pathways. Notably, hetrombopag effectively up-regulated G1 -phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalized progression of the cell cycle, and prevented apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Moreover, hetrombopag and TPO acted additively in stimulating TPOR-dependent signalling, promoting cell viability, and preventing apoptosis. Orally administered hetrombopag specifically promoted the viability and growth of 32D-MPL cells in hollow fibres implanted into nude mice with much higher potency than that of the well-known TPOR agonist, eltrombopag, in association with activation of TPOR-dependent signal transduction in vivo. Taken together, our findings indicate that...Continue Reading
References
Jun 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·I VigonM Souyri
Oct 23, 1995·FEBS Letters·Y EzumiM Okuma
Sep 2, 1994·Science·A L GurneyM W Moore
Feb 1, 1996·The Journal of Experimental Medicine·F J de SauvageM W Moore
May 1, 1999·The Journal of Biological Chemistry·J G DrachmanK Kaushansky
Nov 24, 2001·Blood·J LiD J Kuter
May 29, 2002·Oncogene·Kenneth Kaushansky, Jonathan G Drachman
Nov 2, 2002·Blood·David J Kuter, C Glenn Begley
Jun 24, 2004·Seminars in Cell & Developmental Biology·Julian Downward
Sep 30, 2006·Transfusion Medicine Reviews·Marloes R TijssenJaap Jan Zwaginga
Mar 1, 2007·Blood·Julian M JenkinsConnie L Erickson-Miller
Mar 27, 2007·Cell·Kylie D MasonBenjamin T Kile
Nov 30, 2007·The New England Journal of Medicine·James B BusselJulian M Jenkins
Aug 30, 2008·Haematologica·Wataru NogamiYoshitaka Miyakawa
Nov 29, 2008·Stem Cells·Connie L Erickson-MillerJulian M Jenkins
Jan 24, 2009·Journal of Natural Products·Qiuwen MiSteven M Swanson
Feb 24, 2009·Lancet·James B BusselMichael Arning
Jul 31, 2009·Annual Review of Medicine·David J Kuter
Aug 27, 2010·Lancet·Gregory ChengJames B Bussel
Nov 19, 2010·Expert Review of Hematology·Elizabeth Rhodes, Roberto Stasi
Sep 14, 2011·The Journal of Experimental Medicine·Emma C JosefssonBenjamin T Kile
Jan 25, 2012·Experimental Hematology·Cheng-Ying XieLi-Guang Lou
Aug 9, 2012·Current Opinion in Hematology·Paul A Basciano, James B Bussel
Sep 18, 2012·International Journal of Technology Assessment in Health Care·Katy L CooperRon Akehurst
Aug 19, 2014·American Journal of Hematology·William Beau MitchellJames B Bussel
Sep 19, 2014·International Journal of Hematology·Caizheng Li, Li Zheng
Feb 16, 2015·Haematologica·Muna IraqiBeng H Chong
Apr 19, 2017·Cancer Science·Chengying XieLiguang Lou
May 26, 2017·Basic & Clinical Pharmacology & Toxicology·Li ZhengAn-Bo Xiang
Jan 4, 2018·Oncotarget·Chengying XieLiguang Lou
Citations
Feb 19, 2020·British Journal of Clinical Pharmacology·Guoping YangChan Zou
Oct 29, 2020·Clinical Therapeutics·Zhenlei WangLi Zheng
Feb 27, 2021·Journal of Hematology & Oncology·Heng MeiYu Hu
Aug 7, 2021·Drugs·Yahiya Y Syed
Oct 7, 2021·British Journal of Haematology·David J Kuter
Oct 28, 2021·British Journal of Clinical Pharmacology·Zhenlei WangLi Zheng
Nov 26, 2021·Journal of Thrombosis and Haemostasis : JTH·Heng MeiYu Hu